Literature DB >> 27506452

Adaptive Immune Response Impairs the Efficacy of Autologous Transplantation of Engineered Stem Cells in Dystrophic Dogs.

Clementina Sitzia1, Andrea Farini1, Luciana Jardim2, Paola Razini1, Marzia Belicchi3, Letizia Cassinelli1, Chiara Villa1, Silvia Erratico4, Daniele Parolini1, Pamela Bella1, Joao Carlos da Silva Bizario5, Luis Garcia6, Marcelo Dias-Baruffi2, Mirella Meregalli3, Yvan Torrente7.   

Abstract

Duchenne muscular dystrophy is the most common genetic muscular dystrophy. It is caused by mutations in the dystrophin gene, leading to absence of muscular dystrophin and to progressive degeneration of skeletal muscle. We have demonstrated that the exon skipping method safely and efficiently brings to the expression of a functional dystrophin in dystrophic CD133+ cells injected scid/mdx mice. Golden Retriever muscular dystrophic (GRMD) dogs represent the best preclinical model of Duchenne muscular dystrophy, mimicking the human pathology in genotypic and phenotypic aspects. Here, we assess the capacity of intra-arterial delivered autologous engineered canine CD133+ cells of restoring dystrophin expression in Golden Retriever muscular dystrophy. This is the first demonstration of five-year follow up study, showing initial clinical amelioration followed by stabilization in mild and severe affected Golden Retriever muscular dystrophy dogs. The occurrence of T-cell response in three Golden Retriever muscular dystrophy dogs, consistent with a memory response boosted by the exon skipped-dystrophin protein, suggests an adaptive immune response against dystrophin.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27506452      PMCID: PMC5154479          DOI: 10.1038/mt.2016.163

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.

Authors:  Alberto Lerario; Filippo Cogiamanian; Chiara Marchesi; Marzia Belicchi; Nereo Bresolin; Laura Porretti; Yvan Torrente
Journal:  BMC Musculoskelet Disord       Date:  2010-07-11       Impact factor: 2.362

2.  Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation.

Authors:  P B Bach; D Schrag; D M Nierman; D Horak; P White; J W Young; J S Groeger
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

3.  Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect.

Authors:  Kevin M Flanigan; Katie Campbell; Laurence Viollet; Wei Wang; Ana Maria Gomez; Christopher M Walker; Jerry R Mendell
Journal:  Hum Gene Ther       Date:  2013-09       Impact factor: 5.695

4.  Outcome of bone marrow transplantation patients requiring mechanical ventilation.

Authors:  A J Huaringa; F J Leyva; S A Giralt; J Blanco; J Signes-Costa; H Velarde; R E Champlin
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

5.  Bone marrow stromal cells generate muscle cells and repair muscle degeneration.

Authors:  Mari Dezawa; Hiroto Ishikawa; Yutaka Itokazu; Tomoyuki Yoshihara; Mikio Hoshino; Shin-ichi Takeda; Chizuka Ide; Yo-ichi Nabeshima
Journal:  Science       Date:  2005-07-08       Impact factor: 47.728

6.  Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein.

Authors:  Dejia Li; Yongping Yue; Dongsheng Duan
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

7.  Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice.

Authors:  S F Phelps; M A Hauser; N M Cole; J A Rafael; R T Hinkle; J A Faulkner; J S Chamberlain
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

8.  Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy.

Authors:  D J Wells; K E Wells; E A Asante; G Turner; Y Sunada; K P Campbell; F S Walsh; G Dickson
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

9.  Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.

Authors:  Giulio Cossu; Stefano C Previtali; Sara Napolitano; Maria Pia Cicalese; Francesco Saverio Tedesco; Francesca Nicastro; Maddalena Noviello; Urmas Roostalu; Maria Grazia Natali Sora; Marina Scarlato; Maurizio De Pellegrin; Claudia Godi; Serena Giuliani; Francesca Ciotti; Rossana Tonlorenzi; Isabella Lorenzetti; Cristina Rivellini; Sara Benedetti; Roberto Gatti; Sarah Marktel; Benedetta Mazzi; Andrea Tettamanti; Martina Ragazzi; Maria Adele Imro; Giuseppina Marano; Alessandro Ambrosi; Rossana Fiori; Maria Pia Sormani; Chiara Bonini; Massimo Venturini; Letterio S Politi; Yvan Torrente; Fabio Ciceri
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137

10.  The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Julaine M Florence; Michelle Eagle; Eduard Gappmaier; Allan M Glanzman; Robert Spiegel; Jay Barth; Gary Elfring; Allen Reha; Stuart Peltz
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

View more
  13 in total

1.  Immunoglobulin therapy ameliorates the phenotype and increases lifespan in the severely affected dystrophin-utrophin double knockout mice.

Authors:  Bruno Ghirotto Nunes; Flávio Vieira Loures; Heloisa Maria Siqueira Bueno; Erica Baroni Cangussu; Ernesto Goulart; Giuliana Castello Coatti; Elia Garcia Caldini; Antonio Condino-Neto; Mayana Zatz
Journal:  Eur J Hum Genet       Date:  2017-10-27       Impact factor: 4.246

Review 2.  Stem cell therapy for muscular dystrophies.

Authors:  Stefano Biressi; Antonio Filareto; Thomas A Rando
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 3.  Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle.

Authors:  Olivier Boyer; Gillian Butler-Browne; Hector Chinoy; Giulio Cossu; Francesco Galli; James B Lilleker; Alessandro Magli; Vincent Mouly; Rita C R Perlingeiro; Stefano C Previtali; Maurilio Sampaolesi; Hubert Smeets; Verena Schoewel-Wolf; Simone Spuler; Yvan Torrente; Florence Van Tienen
Journal:  Front Genet       Date:  2021-08-02       Impact factor: 4.599

4.  Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; Paulina Langa; Sonia Brodowska; Katarzyna Kozlowska; Kristina Zalants; Katarzyna Budzynska; Ahlke Heydemann
Journal:  Stem Cell Rev Rep       Date:  2022-05-19       Impact factor: 6.692

5.  Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.

Authors:  M Siemionow; J Cwykiel; A Heydemann; J Garcia-Martinez; K Siemionow; E Szilagyi
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

Review 6.  The golden retriever model of Duchenne muscular dystrophy.

Authors:  Joe N Kornegay
Journal:  Skelet Muscle       Date:  2017-05-19       Impact factor: 4.912

7.  HLA Polymorphism Affects Risk of de novo Mutation of dystrophin Gene and Clinical Severity of Duchenne Muscular Dystrophy in a Southern Chinese Population.

Authors:  Huan Li; Lulu Xiao; Liang Wang; Jinfu Lin; Min Luo; Menglong Chen; Ruojie He; Yuling Zhu; Cheng Zhang
Journal:  Front Neurol       Date:  2018-11-15       Impact factor: 4.003

8.  Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; M Malik; P Langa; J Cwykiel; S Brodowska; A Heydemann
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

9.  Defective dystrophic thymus determines degenerative changes in skeletal muscle.

Authors:  Andrea Farini; Clementina Sitzia; Chiara Villa; Barbara Cassani; Luana Tripodi; Mariella Legato; Marzia Belicchi; Pamela Bella; Caterina Lonati; Stefano Gatti; Massimiliano Cerletti; Yvan Torrente
Journal:  Nat Commun       Date:  2021-04-08       Impact factor: 14.919

10.  Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; Joanna Cwykiel; Ahlke Heydemann; Jesus Garcia; Enza Marchese; Krzysztof Siemionow; Erzsebet Szilagyi
Journal:  Stem Cell Rev Rep       Date:  2018-06       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.